Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Merck & Company ( (MRK) ) has shared an announcement.
On May 22, 2026, Merck & Co., Inc. completed an underwritten public offering of multiple tranches of senior notes with maturities ranging from 2028 to 2056, including floating rate notes and fixed-rate notes carrying coupons between 4.300% and 5.850%. The offering, totaling $6 billion in aggregate principal amount, was issued under an existing 2010 indenture with U.S. Bank Trust National Association as trustee, reinforcing Merck’s long-term funding structure and providing substantial capital for its corporate needs.
The transaction comprised $500 million of floating rate notes due 2028, $1 billion of 4.300% notes due 2028, $500 million of 4.650% notes due 2031, $1 billion of 4.950% notes due 2033, $1.5 billion of 5.200% notes due 2036, $500 million of 5.750% notes due 2046, and $1 billion of 5.850% notes due 2056. By accessing the debt capital markets across a wide maturity spectrum, Merck diversified its liability profile, locked in long-dated financing, and signaled continued confidence from bond investors in the company’s credit quality and strategic direction.
The most recent analyst rating on (MRK) stock is a Buy with a $145.00 price target. To see the full list of analyst forecasts on Merck & Company stock, see the MRK Stock Forecast page.
Spark’s Take on MRK Stock
According to Spark, TipRanks’ AI Analyst, MRK is a Neutral.
The score is driven primarily by solid underlying financial performance (strong cash generation and high-margin business) and constructive earnings-call guidance, partially offset by weak technical momentum and reduced valuation clarity from negative P/E tied to earnings volatility and large one-time charges.
To see Spark’s full report on MRK stock, click here.
More about Merck & Company
Merck & Co., Inc. is a global pharmaceutical company that develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products. The company focuses on treating a wide range of conditions and serves healthcare providers, governments, and patients worldwide across human and animal health markets.
Average Trading Volume: 9,525,905
Technical Sentiment Signal: Buy
Current Market Cap: $279.1B
For a thorough assessment of MRK stock, go to TipRanks’ Stock Analysis page.